These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 28407436)

  • 1. Optimal antiretroviral therapy adherence as evaluated by CASE index score tool is associated with virological suppression in HIV-infected adults in Dakar, Senegal.
    Byabene AK; Fortes-Déguénonvo L; Niang K; Manga MN; Bulabula ANH; Nachega JB; Seydi M
    Trop Med Int Health; 2017 Jun; 22(6):776-782. PubMed ID: 28407436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa.
    Fox MP; Berhanu R; Steegen K; Firnhaber C; Ive P; Spencer D; Mashamaite S; Sheik S; Jonker I; Howell P; Long L; Evans D
    Trop Med Int Health; 2016 Sep; 21(9):1131-7. PubMed ID: 27383454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Socioeconomic factors explain suboptimal adherence to antiretroviral therapy among HIV-infected Australian adults with viral suppression.
    Siefried KJ; Mao L; Kerr S; Cysique LA; Gates TM; McAllister J; Maynard A; de Wit J; Carr A;
    PLoS One; 2017; 12(4):e0174613. PubMed ID: 28369066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi.
    Ongubo DM; Lim R; Tweya H; Stanley CC; Tembo P; Broadhurst R; Gugsa S; Ngongondo M; Speight C; Heller T; Phiri S; Hosseinipour MC
    BMC Infect Dis; 2017 Jul; 17(1):461. PubMed ID: 28673254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
    Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
    HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High turnaround times and low viral resuppression rates after reinforced adherence counselling following a confirmed virological failure diagnostic algorithm in HIV-infected patients on first-line antiretroviral therapy from Tanzania.
    Kroidl A; Burger T; Urio A; Mugeniwalwo R; Mgaya J; Mlagalila F; Hoelscher M; Däumer M; Salehe O; Sangare A; Lennemann T; Maganga L
    Trop Med Int Health; 2020 May; 25(5):579-589. PubMed ID: 31984634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and determinants of adherence to antiretroviral treatment among HIV patients on first-line regimen: a cross-sectional study in Dakar, Senegal.
    Mbengue MAS; Sarr SO; Diop A; Ndour CT; Ndiaye B; Mboup S
    Pan Afr Med J; 2019; 33():95. PubMed ID: 31489073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV viral suppression in TREAT Asia HIV Observational Database enrolled adults on antiretroviral therapy at the Social Health Clinic, the National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia.
    Boettiger DC; Khol V; Durier N; Law M; Sun LP
    Antivir Ther; 2016; 21(8):725-730. PubMed ID: 27124891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved virological suppression in children on antiretroviral treatment receiving community-based adherence support: a multicentre cohort study from South Africa.
    Fatti G; Shaikh N; Eley B; Grimwood A
    AIDS Care; 2014 Apr; 26(4):448-53. PubMed ID: 24215157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and determinants of virological failure in HIV-infected children on antiretroviral therapy in rural Cameroon: a cross-sectional study.
    Zoufaly A; Fillekes Q; Hammerl R; Nassimi N; Jochum J; Drexler JF; Awasom CN; Sunjoh F; Burchard GD; Burger DM; van Lunzen J; Feldt T
    Antivir Ther; 2013; 18(5):681-90. PubMed ID: 23502762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virological outcomes of antiretroviral therapy in Zomba central prison, Malawi; a cross-sectional study.
    Mpawa H; Kwekwesa A; Amberbir A; Garone D; Divala OH; Kawalazira G; van Schoor V; Ndindi H; van Oosterhout JJ
    J Int AIDS Soc; 2017 Aug; 20(1):21623. PubMed ID: 28782332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-sectional study.
    Afrane AKA; Goka BQ; Renner L; Yawson AE; Alhassan Y; Owiafe SN; Agyeman S; Sagoe KWC; Kwara A
    BMC Infect Dis; 2021 Aug; 21(1):731. PubMed ID: 34340689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of targeted viral load testing in diagnosing virological failure in children on antiretroviral therapy with immunological failure.
    Davies MA; Boulle A; Technau K; Eley B; Moultrie H; Rabie H; Garone D; Giddy J; Wood R; Egger M; Keiser O;
    Trop Med Int Health; 2012 Nov; 17(11):1386-90. PubMed ID: 22974345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting: which best predicts virological and resistance outcomes?
    Orrell C; Cohen K; Leisegang R; Bangsberg DR; Wood R; Maartens G
    AIDS Res Ther; 2017 Apr; 14(1):20. PubMed ID: 28376815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A targeted approach for routine viral load monitoring in Malawian adults on antiretroviral therapy.
    Mungwira RG; Divala TH; Nyirenda OM; Kanjala M; Muwalo F; Mkandawire FA; Choko A; Taylor TE; Mallewa J; van Oosterhout JJ; Laufer MK; Laurens MB
    Trop Med Int Health; 2018 May; 23(5):526-532. PubMed ID: 29505108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Current CD4+ T Cell Count Predicts Suboptimal Adherence to Antiretroviral Therapy.
    Pasternak AO; de Bruin M; Bakker M; Berkhout B; Prins JM
    PLoS One; 2015; 10(10):e0140791. PubMed ID: 26468956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda.
    Ndahimana Jd; Riedel DJ; Mwumvaneza M; Sebuhoro D; Uwimbabazi JC; Kubwimana M; Mugabo J; Mulindabigwi A; Kirk C; Kanters S; Forrest JI; Jagodzinski LL; Peel SA; Ribakare M; Redfield RR; Nsanzimana S
    Trop Med Int Health; 2016 Jul; 21(7):928-35. PubMed ID: 27125473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Influencing Antiretroviral Adherence and Virological Outcomes in People Living with HIV in the Highlands of Papua New Guinea.
    Gare J; Kelly-Hanku A; Ryan CE; David M; Kaima P; Imara U; Lote N; Crowe SM; Hearps AC
    PLoS One; 2015; 10(8):e0134918. PubMed ID: 26244516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.
    O'Connor JL; Gardner EM; Esser S; Mannheimer SB; Lifson AR; Telzak EE; Phillips AN;
    HIV Med; 2016 Feb; 17(2):124-32. PubMed ID: 26186609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies.
    Braithwaite RS; Kozal MJ; Chang CC; Roberts MS; Fultz SL; Goetz MB; Gibert C; Rodriguez-Barradas M; Mole L; Justice AC
    AIDS; 2007 Jul; 21(12):1579-89. PubMed ID: 17630553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.